Losartan shows limited benefit in preclinical models of Geleophysic dysplasia

Alejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin · 2026

Read Losartan shows limited benefit in preclinical models of Geleophysic dysplasia by Alejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13574788.txt.

Description

Alejo A Morales, with six colleagues, reports a 2026 test of a common blood-pressure drug in lab models of a rare bone disorder. Geleophysic dysplasia stunts growth, stiffens joints, and strains the heart and lungs, often killing young. Faults in three genes tangle the tissue mesh and may overdrive a growth signal the drug is known to calm.

Losartan blocks a hormone receptor and has eased similar signal-driven disease in other settings. The team gave it in preclinical models of this dysplasia to judge benefit before any human use. Rare-disease drugs often jump from such models straight to small trials, so a clear lab verdict matters. The title states the outcome plainly: benefit was limited in these models. The work steers the field away from a tempting shortcut and toward targets with firmer ground.

Catalog record

CREATORAlejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50804
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13574788

Browse the full library · About the Tower of Babel